Vol.3 No.14 2005/07/28 2005/07/20 1. FDA MedWatch 2005/07/08 2005 Safety Alert:[ Cialis ] tadalafil [ Levitra ] vardenafil hydrochloride [ Viagra ] sildenafil citrate [ Cialis ] tadalafil [ Levitra ] vardenafil hydrochloride [ Viagra ] sildenafil citrate
PDE5 cGMP-specific type 5 phosphodiesterase
PDE5 cGMP-specific type 5 phosphodiesterase
PDE5 cGMP-specific type 5 phosphodiesterase
2. FDA Public Health Advisory 2005/07/13 Suspended Marketing of [ Palladone ] hydromorphone hydrochloride, extended release capsules [ Palladone ] hydromorphone hydrochloride 3. Alert for Healthcare Professionals 2005/07/15 Fentanyl Transdermal System marketed as [ Duragesic ] Fentanyl [ Duragesic ] FDA ALERT [07/2005]: Narcotic Overdose and Death 3-1 FDA MedWatch 2005/07/08 2005 Safety Alert: [ Duragesic ] fentanyl transdermal system [ Duragesic ] fentanyl transdermal system 3-2 FDA Public Health Advisory 2005/07/15 Safety Warnings Regarding Use of Fentanyl Transdermal Skin Patches Fentanyl 4. CDER 2005/07/18 Summaries of Medical and Clinical Pharmacology Reviews of Pediatric Studies as of July 18, 5.FDA MedWatch 2005/07/18 2005 Safety Alert: [ Natrecor ] nesiritide [ Natrecor ] nesiritide 6. FDA Public Health Advisory 2005/07/19 Sepsis and Medical Abortion [ Mifeprex ] mifepristone [ Mifeprex ] mifepristone 7. FDA MedWatch 2005/07/01 Important Drug Warning Regarding [ Raptiva ] efalizumab [ Raptiva ] efalizumab Health Canada 1. Public Advisory 2005/07/04 New Safety Information on the Use of [ Depo-Provera ] medroxyprogesterone acetate suspension for injection, 150 mg IM associated with Bone Mineral Density Changes [ Depo-Provera ] medroxyprogesterone acetate Important Safety Update: Potential effect of [ Depo-Provera ] medroxyprogesterone acetate injectable suspension, USP on Bone Mineral Density BMD changes in adults and adolescents 2005/07/07 [ Depo-Provera ] medroxyprogesterone 2. Public Advisory 2005/07/07 Reminder: Canadian Requirements for White Blood Cell Monitoring for Patients Taking [ Clozaril ] clozapine Tablets. [ Clozaril ] clozapine
MARTA multi acting receptor targeted agents
3. Advisory 2005/07/12 Health Canada advises consumers about important safety information on statins Health Canada 4. Warning 2005/07/14 Health Canada warns consumers not to use certain Ayurvedic medicinal products Health Canada
Journal of the American Medical Association JAMA
5. New safety information regarding the co-administration of [‘Videx’] and [‘Viread’], and either [‘Sustiva’] or [‘Viramune’] 2005/07/18 [ Videx ] didanosine ddI [ Viread ] tenofovir disoproxil fumarate TDF [ Sustiva ] efavirenz EFV [ Viramune ] nevirapine NVP
[ Viread ] tenofovir disoproxil fumarate TDF
NZ MEDSAFE 1. Prescriber Update Vol.26 No.1 2005/06 Prescribing restrictions for all COX-2 inhibitors 2005/04/29
Medicines Adverse Reactions Committee MARC
Smart Policing Initiative Podcast: Glendale, AZ Phase I Lieutenant Frank Balkcom, Glendale Police Department Dr. Michael White, Research Partner, Arizona State University September 2011 [Beginning of transcript] Lt. Frank Balkcom: Lt. Frank Balkcom, Glendale Police Department. Dr. Michael White: I’m Mike White from Arizona State University. Lt. Frank Balkcom: One of the many suc
GEBRAUCHSINFORMATION Advantix® Spot-on Lösung zum Auftropfen auf die Haut für Hunde NAME UND ANSCHRIFT DES ZULASSUNGSINHABERS UND, WENN UNTERSCHIEDLICH, DES HERSTELLERS, DER FÜR DIE CHARGENFREIGABE VERANTWORTLICH IST Zulassungsinhaber: Bayer Vital GmbH Geschäftsbereich Tiergesundheit D-51368 Leverkusen Für die Chargenfreigabe verantwortlicher Hersteller: KVP Pharma + Vete